F. Llorens

发表

Unbalanced activation of ERK1/2 and MEK1/2 in apigenin-induced HeLa cell death.

F. Miró, N. Roher, M. Plana, 2004, Experimental cell research.

Persistent nuclear accumulation of protein kinase CK2 during the G1-phase of the cell cycle does not depend on the ERK1/2 pathway but requires active protein synthesis.

F. Miró, N. Roher, M. Plana, 2002, Archives of biochemistry and biophysics.

A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing

Xavier Estivill, Lauro Sumoy, Lorena Pantano, 2010, Nucleic acids research.

Multiple platform assessment of the EGF dependent transcriptome by microarray and deep tag sequencing analysis

Juliane C. Dohm, J. Dohm, H. Himmelbauer, 2011, BMC Genomics.

Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson’s disease dementia

D. Varges, I. Zerr, F. Llorens, 2018, European Archives of Psychiatry and Clinical Neuroscience.

Dysregulation of brain olfactory and taste receptors in AD, PSP and CJD, and AD-related model

I. Ferrer, F. Llorens, E. Asó, 2013, Neuroscience.

Plasma neurofilament light chain as a biomarker for fatal familial insomnia

I. Zerr, F. Llorens, M. Schmitz, 2022, European journal of neurology.

Sema3E/PlexinD1 regulates the migration of hem-derived Cajal-Retzius cells in developing cerebral cortex

J. D. del Río, Yutaka Yoshida, F. Llorens, 2014, Nature Communications.

Neurites regrowth of cortical neurons by GSK3β inhibition independently of Nogo receptor 1

J. D. del Río, E. Soriano, F. Llorens, 2010, Journal of neurochemistry.

Fatal familial insomnia: mitochondrial and protein synthesis machinery decline in the mediodorsal thalamus

I. Ferrer, I. Zerr, F. Llorens, 2017, Brain pathology.

Biomarker-based diagnosis of sporadic Creutzfeldt-Jakob disease

Inga, B. Caughey, M. Geschwind, 2021 .

Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry*

S. Carr, S. Schreiber, G. J. Raymond, 2019, Molecular & Cellular Proteomics.

The C-terminal domain of human grp94 protects the catalytic subunit of protein kinase CK2 (CK2alpha) against thermal aggregation. Role of disulfide bonds.

O. Issinger, F. Miró, N. Roher, 2001, European journal of biochemistry.

Identification of new molecular alterations in fatal familial insomnia.

Christopher J. Silva, I. Ferrer, I. Zerr, 2016, Human molecular genetics.

Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease

D. Varges, I. Zerr, F. Llorens, 2022, Molecular Neurobiology.

PrP mRNA and protein expression in brain and PrPc in CSF in Creutzfeldt-Jakob disease MM1 and VV2

J. Yagüe, J. D. del Río, I. Zerr, 2013, Prion.

Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic

A. Karch, J. Laplanche, I. Zerr, 2016, Molecular Neurobiology.

RCAN1 (DSCR1) increases neuronal susceptibility to oxidative stress: a potential pathogenic process in neurodegeneration.

X. Estivill, F. Llorens, M. Valverde, 2007, Human molecular genetics.

A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia

G. Escaramís, J. D. del Río, D. Varges, 2020, Journal of Neurology.

Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy

J. Trojanowski, V. Lee, H. Vanderstichele, 2018, Molecular Neurobiology.

Eukaryotic translation-initiation factor eIF2β binds to protein kinase CK2: effects on CK2α activity

F. Miró, N. Roher, M. Plana, 2003 .

Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies

D. Varges, I. Zerr, F. Llorens, 2021, Frontiers in Aging Neuroscience.

Neuroprotective role of PrPC against kainate-induced epileptic seizures and cell death depends on the modulation of JNK3 activation by GluR6/7–PSD-95 binding

I. Ferrer, J. D. del Río, F. Llorens, 2011, Molecular biology of the cell.

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline

B. Mollenhauer, D. Varges, I. Zerr, 2022, Diagnostics.

Cellular Prion Protein Mediates α‐Synuclein Uptake, Localization, and Toxicity In Vitro and In Vivo

Christopher J. Silva, I. Zerr, W. Möbius, 2021, Movement disorders : official journal of the Movement Disorder Society.

A prognostic model for overall survival in sporadic Creutzfeldt‐Jakob disease

A. Karch, I. Zerr, F. Llorens, 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Unraveling the neuroprotective mechanisms of PrPC in excitotoxicity

J. D. del Río, F. Llorens, 2012, Prion.

Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations

I. Ferrer, I. Zerr, F. Llorens, 2017, Current Neurology and Neuroscience Reports.

Hereditary Human Prion Diseases: an Update

W. Schulz-Schaeffer, I. Zerr, F. Llorens, 2016, Molecular Neurobiology.

PP1/PP2A phosphatases inhibitors okadaic acid and calyculin A block ERK5 activation by growth factors and oxidative stress

E. Itarte, F. Llorens, L. Garcia, 2002, FEBS letters.

Validation of Poly(Propylene Imine) Glycodendrimers Towards Their Anti-prion Conversion Efficiency

I. Zerr, D. Dafou, T. Sklaviadis, 2019, Molecular Neurobiology.

Prion protein quantification in cerebrospinal fluid as a tool for prion disease therapeutic development

S. Schreiber, E. Minikel, S. Arnold, 2019 .

Prion protein quantification in cerebrospinal fluid as a tool for prion disease drug development

S. Schreiber, E. Minikel, S. Arnold, 2018, bioRxiv.

Application of an in vitro-amplification assay as a novel pre-screening test for compounds inhibiting the aggregation of prion protein scrapie

D. Varges, W. Schulz-Schaeffer, I. Zerr, 2016, Scientific Reports.

BAMBI and CHGA in Prion Diseases: Neuropathological Assessment and Potential Role as Disease Biomarkers

J. Toivonen, I. Zerr, R. Bolea, 2020, Biomolecules.

The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases

B. Caughey, W. Schulz-Schaeffer, I. Zerr, 2016, Nature Protocols.

The N-terminal domain of the human eIF2beta subunit and the CK2 phosphorylation sites are required for its function.

N. Roher, M. Plana, E. Itarte, 2006, The Biochemical journal.

Involvement of PrPC in kainate-induced excitotoxicity in several mouse strains

J. D. del Río, G. Legname, F. Llorens, 2015, Scientific Reports.

Variably protease‐sensitive prionopathy presenting within ALS/FTD spectrum

I. Zerr, R. Sánchez-Valle, F. Llorens, 2018, Annals of clinical and translational neurology.

Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease

B. Caughey, I. Zerr, M. Geschwind, 2021, The Lancet Neurology.

Role of the Cellular Prion Protein in Oligodendrocyte Precursor Cell Proliferation and Differentiation in the Developing and Adult Mouse CNS

J. García-Verdugo, J. D. del Río, F. Llorens, 2012, PloS one.

The role of cellular prion protein in lipid metabolism in the liver

I. Zerr, F. Llorens, Prateek Kumar, 2020, Prion.

Amplification and Detection of Minuscule Amounts of Misfolded Prion Protein by Using the Real-Time Quaking-Induced Conversion.

I. Zerr, F. Llorens, M. Schmitz, 2018, Methods in molecular biology.

Reelin Expression in Creutzfeldt-Jakob Disease and Experimental Models of Transmissible Spongiform Encephalopathies

I. Ferrer, I. Zerr, F. Llorens, 2017, Molecular Neurobiology.

Application of capillary immunoelectrophoresis revealed an age‐ and gender‐dependent regulated expression of PrPC in liver

I. Zerr, F. Llorens, Prateek Kumar, 2015, Electrophoresis.

RNA editing alterations define manifestation of prion diseases

I. Zerr, D. Dafou, S. Bonn, 2019, Proceedings of the National Academy of Sciences.

Cerebrospinal fluid neurogranin as a new player in prion disease diagnosis and prognosis

I. Zerr, F. Llorens, A. Villar-Piqué, 2019, Neural regeneration research.

Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development

S. Schreiber, E. Minikel, S. Arnold, 2019, Proceedings of the National Academy of Sciences.

Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases

A. Karch, I. Zerr, I. Santana, 2018, Molecular Neurobiology.

Subtype and Regional-Specific Neuroinflammation in Sporadic Creutzfeldt–Jakob Disease

I. Zerr, F. Llorens, I. Ferrer, 2014, Front. Aging Neurosci..

CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD

K. Blennow, A. Karch, I. Zerr, 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

Title CSF neurogranin as a neuronal damage marker in CJD : A comparative study with AD Running head Neurogranin in the CSF and brain of AD and CJD

K. Blennow, I. Ferrer, A. Karch, 2019 .

A highly expressed miR-101 isomiR is a functional silencing small RNA

Xavier Estivill, Lorena Pantano, Isidre Ferrer, 2013, BMC Genomics.

Plasma YKL-40 in the spectrum of neurodegenerative dementia

D. Varges, I. Zerr, F. Llorens, 2019, Journal of Neuroinflammation.

Analysis of co-isogenic prion protein deficient mice reveals behavioral deficits, learning impairment, and enhanced hippocampal excitability

A. Aguzzi, J. D. del Río, A. Gruart, 2022, BMC biology.

Behavioral deficits, learning impairment, and enhanced hippocampal excitability in co-isogenic PrnpZH3/ZH3 mice

I. Ferrer, A. Aguzzi, A. Gruart, 2021, bioRxiv.

Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis

I. Ferrer, I. Zerr, I. Santana, 2020, International journal of molecular sciences.

Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice: Correlations With Plaques, Tangles, and Oligomeric Species

M. Portero-Otín, F. Llorens, A. Fuso, 2015, Journal of neuropathology and experimental neurology.

Chapter 9 New Frontiers in Alzheimer ' s Disease Diagnosis

I. Zerr, F. Llorens, K. Stoeck, 2018 .

MicroRNA Expression in the Locus Coeruleus, Entorhinal Cortex, and Hippocampus at Early and Middle Stages of Braak Neurofibrillary Tangle Pathology

I. Ferrer, I. Zerr, F. Llorens, 2017, Journal of Molecular Neuroscience.

New Frontiers in Alzheimer's Disease Diagnosis

I. Zerr, F. Llorens, K. Stoeck, 2015 .

TREM2 expression in the brain and biological fluids in prion diseases

K. Blennow, B. Mollenhauer, J. D. del Río, 2021, Acta Neuropathologica.

Regulation of GABAA and Glutamate Receptor Expression, Synaptic Facilitation and Long-Term Potentiation in the Hippocampus of Prion Mutant Mice

José María Delgado-García, Lauro Sumoy, Rosalina Gavín, 2009, PloS one.

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias

I. Ferrer, I. Zerr, R. Sánchez-Valle, 2017, Molecular Neurodegeneration.

I. Ferrer, J. D. del Río, E. Sabidó, 2018, Brain pathology.

Microarray and deep sequencing cross-platform analysis of the mirRNome and isomiR variation in response to epidermal growth factor

Robert Kofler, Lauro Sumoy, Manuela Hummel, 2013, BMC Genomics.

Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt–Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress

B. Mollenhauer, I. Zerr, F. Llorens, 2016, Molecular Neurobiology.

YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression

F. Llorens, I. Ferrer, M. Colomina, 2018, Aging.

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia

I. Zerr, F. Llorens, A. Fischer, 2017, Front. Aging Neurosci..

Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases

B. Mollenhauer, P. Liberski, D. Varges, 2017, Alzheimer's & Dementia.

Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease

A. Karch, B. Mollenhauer, P. Liberski, 2017, Molecular Neurobiology.

Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients

I. Zerr, F. Llorens, I. Ferrer, 2016, Aging.

Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies

B. Mollenhauer, D. Varges, I. Zerr, 2016, Journal of Neurology.

Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia

A. Karch, D. Varges, I. Zerr, 2016, Alzheimer's & Dementia.

MicroRNA 22 Regulates Cell Cycle Length in Cerebellar Granular Neuron Precursors

F. Llorens, S. Pons, L. Sumoy, 2013, Molecular and Cellular Biology.

Title Page Title: Mir-22 Regulates Cell-cycle Length in Cerebellar Granular Neuron Precursors. 3 4 Affiliation: Running Title: Mir-22 Regulates Cell Cycle Length

F. Llorens, S. Pons, L. Sumoy, 2013 .

Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis

J. Díez, J. D. del Río, I. Zerr, 2018, PLoS pathogens.

in Cerebellar Granular Neuron Precursors MicroRNA 22 Regulates Cell Cycle Length

F. Llorens, S. Pons, L. Sumoy, 2014 .

Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies

F. Llorens, I. Ferrer, P. Garcia-Esparcia, 2016, International journal of molecular sciences.

An Update on Autophagy in Prion Diseases

I. Ferrer, R. Bolea, J. Badiola, 2020, Frontiers in Bioengineering and Biotechnology.

Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD

B. Mollenhauer, I. Zerr, F. Llorens, 2015, Journal of Neurology.

Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases

A. Lleó, P. Pástor, I. Zerr, 2020, Cells.

Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease

I. Zerr, F. Llorens, D. Sepulveda-Falla, 2020, International journal of molecular sciences.

Mitochondrial DNA differentiates Alzheimer's disease from Creutzfeldt-Jakob disease

P. Liberski, I. Zerr, F. Llorens, 2016, Alzheimer's & Dementia.

Huntington’s disease brain-derived small RNAs recapitulate associated neuropathology in mice

G. Escaramís, L. Pantano, F. Llorens, 2021, Acta Neuropathologica.

Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease

P. Liberski, I. Zerr, S. Bonn, 2017, Acta Neuropathologica Communications.

Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt–Jakob disease

I. Zerr, F. Llorens, I. Ferrer, 2015, Neuropathology and applied neurobiology.

Proteomic analysis of SET‐binding proteins

O. Bachs, E. Itarte, F. Llorens, 2007, Proteomics.

Gene Expression Resulting from PrPC Ablation and PrPC Overexpression in Murine and Cellular Models

F. Llorens, I. Ferrer, J. A. Rı́o, 2014, Molecular Neurobiology.

Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases

I. Zerr, S. Ventura, F. Llorens, 2018, Molecular Neurobiology.

Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry*

S. Carr, S. Schreiber, G. J. Raymond, 2019, Molecular & Cellular Proteomics.

Tau Protein as a Biological Fluid Biomarker in Neurodegenerative Dementias

I. Zerr, F. Llorens, I. Ferrer, 2018, Cognitive Disorders.

Cerebrospinal Fluid Biomarker-Based Diagnosis of Sporadic Creutzfeldt-Jakob Disease: A Validation Study for Previously Established Cutoffs

A. Karch, P. Liberski, I. Zerr, 2017, Dementia and Geriatric Cognitive Disorders.

Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic

A. Karch, J. Laplanche, I. Zerr, 2016, Molecular Neurobiology.

Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases

P. Liberski, I. Zerr, F. Llorens, 2020, Neuropathology and applied neurobiology.

Sporadic Creutzfeldt–Jakob disease with glial PrPRes nuclear and perinuclear immunoreactivity

I. Ferrer, F. Llorens, R. Juste, 2018, Neuropathology : official journal of the Japanese Society of Neuropathology.

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease

K. Blennow, S. Lehmann, B. Mollenhauer, 2018, Alzheimer's & dementia.

Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases

K. Blennow, I. Ferrer, A. Karch, 2018, Alzheimer's & Dementia.

Cerebrospinal fluid in Creutzfeldt-Jakob disease.

I. Zerr, F. Llorens, M. Schmitz, 2017, Handbook of clinical neurology.

Altered Mitochondria, Protein Synthesis Machinery, and Purine Metabolism Are Molecular Contributors to the Pathogenesis of Creutzfeldt–Jakob Disease

I. Ferrer, I. Zerr, F. Llorens, 2016, Journal of neuropathology and experimental neurology.

Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease

I. Zerr, F. Brett, F. Llorens, 2020, Biomolecules.

Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease

I. Ferrer, A. Karch, P. Liberski, 2019, Journal of Clinical Neuroscience.

Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease

K. Blennow, D. Varges, I. Zerr, 2021, Alzheimer's Research & Therapy.

Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases

G. Escaramís, B. Mollenhauer, P. Liberski, 2022, Brain : a journal of neurology.

Optimization of the Real-Time Quaking-Induced Conversion Assay for Prion Disease Diagnosis

I. Zerr, F. Llorens, M. Schmitz, 2020, Frontiers in Bioengineering and Biotechnology.

Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients

I. Zerr, I. Santana, R. Sánchez-Valle, 2019, Biomolecules.

Cerebrospinal fluid non-phosphorylated tau in the differential diagnosis of Creutzfeldt–Jakob disease: a comparative prospective study with 14-3-3

I. Zerr, F. Llorens, I. Lachmann, 2019, Journal of Neurology.

Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie

I. Zerr, R. Bolea, J. Badiola, 2018, Molecular Neurobiology.

Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies

I. Zerr, F. Llorens, M. Schmitz, 2017, Expert review of molecular diagnostics.

CSF biomarkers in neurodegenerative and vascular dementias

I. Ferrer, I. Zerr, F. Llorens, 2016, Progress in Neurobiology.

The cellular prion protein and its derived fragments in human prion diseases and their role as potential biomarkers

I. Zerr, F. Llorens, M. Glatzel, 2019, Expert review of molecular diagnostics.

Cerebrospinal fluid tau levels are a marker for molecular subtype in sporadic Creutzfeldt-Jakob disease

A. Karch, I. Zerr, F. Llorens, 2015, Neurobiology of Aging.

Plasma YKL-40 in the spectrum of neurodegenerative dementia

D. Varges, I. Zerr, F. Llorens, 2019, Journal of Neuroinflammation.

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays

H. Vanderstichele, I. Zerr, F. Llorens, 2020, Translational Neurodegeneration.

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays

H. Vanderstichele, I. Zerr, F. Llorens, 2020, Translational Neurodegeneration.

Seeding variability of different alpha synuclein strains in synucleinopathies

I. Zerr, W. Möbius, F. Llorens, 2019, Annals of neurology.

Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia.

A. Karch, I. Zerr, F. Llorens, 2016, Journal of Alzheimer's disease : JAD.

Developmental analysis of Lingo‐1/Lern1 protein expression in the mouse brain: Interaction of its intracellular domain with Myt1l

X. Estivill, J. D. del Río, E. Soriano, 2008, Developmental neurobiology.

Creutzfeldt-Jakob Disease Subtype-Specific Regional and Temporal Regulation of ADP Ribosylation Factor-1-Dependent Rho/MLC Pathway at Pre-Clinical Stage

I. Zerr, F. Llorens, I. Ferrer, 2015, Journal of Molecular Neuroscience.

PrPC regulates epidermal growth factor receptor function and cell shape dynamics in Neuro2a cells

J. D. del Río, F. Llorens, P. Fortes, 2013, Journal of neurochemistry.

Emerging functions of myelin‐associated proteins during development, neuronal plasticity, and neurodegeneration

F. Llorens, J. Río, Vanessa Gil, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Developmental expression of the oligodendrocyte myelin glycoprotein in the mouse telencephalon.

J. D. del Río, B. Zheng, E. Soriano, 2010, Cerebral cortex.

Ecto-GPR37: a potential biomarker for Parkinson’s disease

P. Svenningsson, F. Ciruela, I. Ferrer, 2021, Translational Neurodegeneration.

Ecto-GPR37: a potential biomarker for Parkinson’s disease

P. Svenningsson, F. Ciruela, I. Ferrer, 2021, Translational neurodegeneration.

Apigenin and LY294002 prolong EGF‐stimulated ERK1/2 activation in PC12 cells but are unable to induce full differentiation

E. Itarte, F. Llorens, L. Garcia, 2002, FEBS letters.

Complex Deregulation and Expression of Cytokines and Mediators of the Immune Response in Parkinson's Disease Brain is Region Dependent

F. Llorens, I. Ferrer, M. Carmona, 2014, Brain pathology.

Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms

I. Ferrer, J. D. del Río, I. Zerr, 2017, Front. Neurol..

The carboxy‐terminal domain of Grp94 binds to protein kinase CK2α but not to CK2 holoenzyme

Lorenzo A. Pinna, F. Miró, N. Roher, 2001 .

Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases

I. Zerr, S. Ventura, F. Llorens, 2018, Molecular Neurobiology.

Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue

B. Saez, F. Mateo, J. Moss, 2021, Molecular Cancer Research.

Creutzfeldt-Jakob Disease Subtype-Specific Regional and Temporal Regulation of ADP Ribosylation Factor-1-Dependent Rho/MLC Pathway at Pre-Clinical Stage

I. Zerr, F. Llorens, I. Ferrer, 2015, Journal of Molecular Neuroscience.

Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease

P. Liberski, I. Zerr, S. Bonn, 2017, Acta neuropathologica communications.

Cross talk between protein kinase CK2 and eukaryotic translation initiation factor eIF2β subunit

Lorenzo A. Pinna, N. Roher, M. Plana, 2005, Molecular and Cellular Biochemistry.

MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives

I. Zerr, D. Dafou, T. Sklaviadis, 2018, Front. Aging Neurosci..

Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers

D. Varges, I. Zerr, I. Santana, 2022, Alzheimer's research & therapy.

Increased albumin CSF/serum ratio in dementia with Lewy bodies

D. Varges, I. Zerr, F. Llorens, 2015, Journal of the Neurological Sciences.

Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies

I. Ferrer, F. Llorens, M. Carmona, 2018, Front. Aging Neurosci..

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD

P. Lewczuk, J. Kornhuber, I. Zerr, 2018, Annals of clinical and translational neurology.

Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry.

S. Carr, S. Schreiber, G. J. Raymond, 2019, Molecular & cellular proteomics : MCP.

Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases

A. Karch, I. Zerr, I. Santana, 2018, Molecular Neurobiology.

Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy

J. Trojanowski, V. Lee, H. Vanderstichele, 2018, Molecular Neurobiology.

Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy

I. Zerr, F. Llorens, M. Schmitz, 2015, Neurobiology of Aging.

Validation of Poly(Propylene Imine) Glycodendrimers Towards Their Anti-prion Conversion Efficiency

I. Zerr, D. Dafou, T. Sklaviadis, 2019, Molecular Neurobiology.

Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie

I. Zerr, R. Bolea, J. Badiola, 2018, Molecular Neurobiology.

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia

K. Blennow, I. Ferrer, O. Hansson, 2020, Nature Communications.

Haploinsufficiency of the Myc regulator Mtbp extends survival and delays tumor development in aging mice

Hayes, Grogan, Stricker, 2016, Aging.

Eukaryotic translation-initiation factor eIF2beta binds to protein kinase CK2: effects on CK2alpha activity.

F. Miró, N. Roher, M. Plana, 2003, The Biochemical journal.